Rivaroxaban Dosing Considerations in Pulmonary Embolism
Standard Dosing and Renal Function
- The European Society of Cardiology recommends rivaroxaban 15 mg twice daily for the first 21 days, followed by 20 mg once daily for continued treatment in patients with normal renal function or mild-to-moderate renal impairment (CrCl ≥30 mL/min) 1
Dosing Adjustments Based on Renal Function
- Rivaroxaban has 33% renal clearance, making it moderately dependent on kidney function, and increased monitoring is prudent as drug accumulation can occur in patients with moderate renal impairment (CrCl 30-50 mL/min) 2
- The European Society of Cardiology suggests considering dose reduction or alternative anticoagulation in patients with severe renal impairment (CrCl 15-29 mL/min) due to the lack of clinical trial data in this population 1
Alternative Anticoagulation Options
- Apixaban can be used with dose reduction (2.5 mg twice daily) in severe CKD and even in dialysis patients, as it has only 27% renal clearance, making it a safer alternative to rivaroxaban in patients with CrCl <30 mL/min 3
Extended Treatment Considerations
- The European Society of Cardiology recommends reduced-dose rivaroxaban (10 mg once daily) for extended prophylaxis after 6 months of therapeutic anticoagulation in patients without cancer, as it has demonstrated efficacy superior to aspirin for preventing recurrent VTE 4, 5
Special Populations
- Elderly patients (≥75 years) have an increased bleeding risk, particularly gastrointestinal and intracranial hemorrhage, and should be treated with caution, considering a lower threshold for dose reduction if bleeding occurs 6
- Patients requiring surgery should stop rivaroxaban 2 days before surgery (approximately 4 half-lives) in normal renal function, and longer interruption is required with renal impairment, with a minimum of 3-4 days 2